肝硬化失代偿期患者使用阿德福韦酯的临床疗效分析

Clinical analysis of the efficacy of the adefovir dipivoxil treatment on decompensated cirrhosis

目的:探讨阿德福韦酯治疗肝硬化失代偿期临床效果。方法:选取40例肝硬化失代偿期患者随机分为阿德福韦酯组和常规组,常规组采用常规保肝方法治疗,阿德福韦酯组在常规组治疗基础上采用阿德福韦酯治疗,比较两组患者治疗后肝功能及肝纤维化指标。结果:治疗后阿德福韦酯组TBIL、ALT、PT水平及Child-Pugh评分均低于常规组,两组比较有统计学意义(P<0.05);治疗后阿德福韦酯组HA、LN、PCⅢ、Ⅳ-C水平均低于常规组,两组间比较有统计学意义(P<0.05)。结论:阿德福韦酯治疗肝硬化失代偿期可改善肝功能,减轻肝纤维化,具有显著治疗效果。

Objective：To investigate the clinical effect of adefovir dipivoxil on treating decompensated cirrhosis.Methods：40 cases of patients with decompensated cirrhosis selected were randomized into the adefovir dipivoxil group and the conventional group.The conventional group adopted the conventional methods for protecting the liver,while the adefovir dipivoxil group were treated with adefovir dipivoxil on the basis of conventional treatment methods.Then the liver functions and liver fibrosis indexes of both groups were compared after the treatment.Results：After treatment,TBIL,ALT,PT level and Child-Pugh score in the adefovir dipivoxil group were lower than those in the conventional group,which were of statistical significances between both groups（P〈0.05）;while HA,LN,PCⅢ,Ⅳ-C levels in the adefovir dipivoxil group were lower than those in conventional group,which were of statistical significances（P〈0.05）.Conclusion：The treatment of decompensated cirrhosis by adefovir dipivoxil may improve the liver functions and reduce the liver fibrosis,which has a substantial clinical curative effect.